Bioaffinity Technologies revenue was $5.66M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2026) ending on Mar 31, 2026 was $1.4M, down 15.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, BIAF annual revenue was $6.2M, with -34.2% growth year-over-year.
BIAF past revenue growth
How has BIAF's revenue growth performed historically?
Bioaffinity Technologies (NASDAQ: BIAF) reported Q1 2026 revenue of $1.35 million up 27.09% year over year. In the same quarter last year, Bioaffinity Technologies's revenue was $1.85 million.
What was Bioaffinity Technologies's revenue in 2025?
Bioaffinity Technologies's annual revenue for the twelve months ending Dec 31, 2025 was $6.16 million, a 34.18% decrease year over year.
How much does Bioaffinity Technologies make in a day?
Based on Bioaffinity Technologies annual revenue for the past five years, BIAF makes an average of $9,896.59 per day.
What was Bioaffinity Technologies's annual revenue growth in the past year?
As of Q2 2026, Bioaffinity Technologies's revenue has grown -35.75% year over year. This is 46.3 percentage points lower than the US Diagnostics & Research industry revenue growth rate of 10.55%. Bioaffinity Technologies's revenue in the past year totaled $5.66 million.
How much does Bioaffinity Technologies make in a year?
Bioaffinity Technologies's revenue by year for the past five years is:
Bioaffinity Technologies's revenue for the twelve months ending Dec 31, 2025 was $6.16 million, a 34.18% decrease year over year.
Bioaffinity Technologies's annual revenue for Dec 31, 2024 was $9.36 million, a 269.68% increase from 2023.
Bioaffinity Technologies's annual revenue for 2023 was $2.53 million, a 52,627.44% increase from 2022.
Bioaffinity Technologies's annual revenue for 2022 was $4.80 thousand, a Infinity% increase from 2021.
Bioaffinity Technologies's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.